Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

The Lancet. Respiratory Medicine
Bruno CrestaniMichael Kreuter

Abstract

The efficacy and safety of nintedanib, an intracellular tyrosine kinase inhibitor, in patients with idiopathic pulmonary fibrosis were assessed in two phase 3, placebo-controlled INPULSIS trials. Patients who completed the 52-week treatment period in an INPULSIS trial could receive open-label nintedanib in the extension trial, INPULSIS-ON. We aimed to assess the long-term efficacy and safety of nintedanib in INPULSIS-ON. Patients who completed the 52-week treatment period of INPULSIS, and the follow-up visit 4 weeks later, were eligible for INPULSIS-ON. The off-treatment period between INPULSIS and INPULSIS-ON could be 4-12 weeks. Patients receiving nintedanib 150 mg twice daily or placebo at the end of an INPULSIS trial received nintedanib 150 mg twice daily in INPULSIS-ON. Patients receiving nintedanib 100 mg twice daily or placebo at the end of an INPULSIS trial could receive nintedanib 100 mg twice daily or 150 mg twice daily in INPULSIS-ON. Spirometric tests were done at baseline, at weeks 2, 4, 6, 12, 24, 36, 48, and then every 16 weeks. The primary outcome of INPULSIS-ON was to characterise the long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis, and this was analysed in patient...Continue Reading

Citations

Jan 12, 2019·Expert Review of Respiratory Medicine·Lykourgos KolilekasDemosthenes Bouros
Jul 23, 2019·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jin Woo SongBruno Crestani
Jun 11, 2019·Expert Review of Respiratory Medicine·Onofre Moran-MendozaIngrid Harle
Oct 1, 2019·Expert Review of Respiratory Medicine·Amornpun WongkarnjanaMartin Rj Kolb
Nov 22, 2019·Modern Rheumatology·Masataka Kuwana, Arata Azuma
Jun 9, 2020·Expert Review of Clinical Immunology·Yoshioki Yamasaki, Masataka Kuwana
Jun 25, 2020·Tuberculosis and Respiratory Diseases·Arata Azuma, Luca Richeldi
Jul 24, 2020·Current Opinion in Pulmonary Medicine·Pierre-Antoine JugePhilippe Dieudé
Jul 24, 2020·Current Opinion in Pulmonary Medicine·Katerina AntoniouJeffrey J Swigris
Sep 8, 2019·Respiratory Research·Toby M Maher, Mary E Strek
Oct 1, 2020·Expert Opinion on Pharmacotherapy·Athina TrachalakiAthol U Wells
Jan 8, 2020·Respiratory Research·Claudia ValenzuelaMichael Kreuter
Feb 23, 2020·Respirology Case Reports·Ryosuke Imai, Yutaka Tomishima
Jul 8, 2020·International Journal of Molecular Sciences·Wei-Chih ChenKuang-Yao Yang
Jun 13, 2020·The European Respiratory Journal·C Arnold Spek, JanWillem Duitman
Aug 8, 2020·Annals of the Rheumatic Diseases·James R SeiboldUNKNOWN SENSCIS trial investigators
May 3, 2019·Journal of Drug Assessment·Aristeidis SkandamisKyriakos Souliotis
Oct 4, 2019·European Respiratory Review : an Official Journal of the European Respiratory Society·Bridget F Collins, Ganesh Raghu
Aug 21, 2019·Journal of Clinical Medicine·Hasancan BilgiliWojciech J Piotrowski
Sep 25, 2020·Respirology : Official Journal of the Asian Pacific Society of Respirology·Yuzo SuzukiTakafumi Suda
Nov 14, 2019·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·António Morais
Dec 13, 2019·Multidisciplinary Respiratory Medicine·Caitlin QuinnStephenie T Manns
Jun 17, 2020·European Radiology·Ana Adriana TrusculescuCristian Oancea
Sep 29, 2019·Journal of Clinical Medicine·JanWillem DuitmanC Arnold Spek
Dec 30, 2020·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva·Marta Librero JiménezMaría Carmen Fernández Cano
Jan 6, 2021·International Journal of Molecular Sciences·Grzegorz GrześkAlicja Nowaczyk
Feb 24, 2021·British Journal of Clinical Pharmacology·Pietro AmeriItalo Porto
Jun 4, 2020·Respiratory Investigation·Daniel S GlassAllison B Reiss
Apr 16, 2021·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·Franck RahaghiJoao A de Andrade

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.